Oncolytics Advances REO 033 with Expanded Sites and Potential FDA Path
Sep 28, 2026, 10:23 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The combination of rapid site activation, an expected interim data readout by year-end, and an FDA-aligned pathway for a potential pivotal Part B could meaningfully de-risk the program and support a re-rating of ONCY contingent on positive interim outcomes and clear regulatory milestones, as seen in biotech peers when trial momentum and regulatory clarity align.
AI summary
What happened, with direct paths to the underlying reporting
Oncolytics Biotech reports near-complete site activation for REO 033 with multiple patients on study and expects interim Part A data by year-end 2026. The company has aligned with the FDA on a potential Part B pivotal expansion that could support accelerated approval based on ORR, with PFS informing full approval. Positive interim signals and a clearer regulatory path could drive near-term re-rating if milestones are met.
Nearly all REO 033 sites activated; patients are enrolled.
Interim Part A data expected by year-end 2026; October evaluable-patient count key.
FDA alignment could support Part B pivotal expansion for accelerated approval via ORR.
REO 033 is randomized vs control to confirm REO 022 signals.
Pelareorep has FDA Fast Track for GI cancers; strategic partnerships under consideration.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Oncolytics Biotech announced a 19.5-month median response duration for pelareorep in colorectal cancer, significantly outperforming historical benchmarks. This data, alongside a p…
